Challenges of Non-Secretory MM
The popular anti-Multiple Myeloma agent Bortezomib (Velcade) has just won FDA approval for subcutaneous injection. This means that it can be administered as a simple injection versus intravenous (IV) infusion. Velcade and it’s subsequent analogs work by being protein i ...